Also trades as: CMND.CN (CNQ) · $vol 0M
CMND NASDAQ
Clearmind Medicine Inc.
1W: +2.0%
1M: -4.7%
3M: -47.6%
YTD: -96.2%
1Y: -99.8%
3Y: -100.0%
$5.97
-0.15 (-2.52%)
After Hours: $6.17 (+0.20, +3.40%)
Weekly Expected Move ±10.3%
$5
$5
$6
$6
$7
Credit Risk of going bust: higher than 97% of companies Debt: 36.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.64 (down 72%), Clearmind Medicine Inc. would be worth roughly what it owes.
Total debt $1.8M against a stock market value of $3.1M.
Distance to default 0.06 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $1.6M (short-term plus half of long-term), stock volatility 171.6%; Altman Z'' -1.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $1.8M against a stock market value of $3.1M.
Distance to default 0.06 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $1.6M (short-term plus half of long-term), stock volatility 171.6%; Altman Z'' -1.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$3.0M
52W Range5.25-3840
Volume5,341
Avg Volume1,663,079
Beta-1.16
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAdi Zuloff-Shani
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2022-11-15
Websiteclearmindmedicine.com
1220 West 6th Avenue
Vancouver, BC V6H 1A5
CA
Vancouver, BC V6H 1A5
CA
604 260 1566
About Clearmind Medicine Inc.
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Latest News
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HRT FINANCIAL LP | S-Sale | 22,139 | $3.31 | 2026-06-16 |
| HRT FINANCIAL LP | S-Sale | 3,183 | $3.32 | 2026-06-15 |
| HRT FINANCIAL LP | S-Sale | 2,102 | $3.36 | 2026-06-12 |
| HRT FINANCIAL LP | 0 | — | 2026-06-10 | |
| Lamadrid David | A-Award | 857,143 | $0.35 | 2017-05-12 |